Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mechanisms of Resistance to Induction Lorlatinib in ALK+ NSCLC
NCT06893354Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- May 2025
- Primary completion
- Jul 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
Phase 4, randomised, open-label trial of lorlatinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Primary endpoint: Single-cell RNA sequencing at 12 weeks. Planned start May 2025; status: not yet recruiting.
02
Drugs
lorlatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06893354.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06893354.